Article Text

Download PDFPDF

4CPS-011 Real-world effectiveness and survival of guselkumab in patients with psoriasis and psoriatic arthritis: multicentre analysis in daily clinical practice by the Valencian Community psoriasis group
  1. J Poquet-Jornet1,
  2. F Rogriguez-Lucena2,
  3. MC Rodriguez-Samper3,
  4. MA Bernabeu-Martinez4,
  5. A Garcia-Monsalvez5,
  6. MA Cia-Barrio6,
  7. M Prieto-Castello7,
  8. R Fuster-Ruiz De Apodaca8,
  9. A Moya-Martinez9
  1. 1Hospital de Denia, Pharmacy, Denia, Spain
  2. 2Hospital Vega Baja, Pharmacy, Orihuela, Spain
  3. 3Hospital General Universitario de Elda, Pharmacy, Elda, Spain
  4. 4Hospital Universitario San Juan, Pharmacy, San Juan, Spain
  5. 5Hospital General Universitario de Elche, Pharmacy, Elche, Spain
  6. 6Hospital Marina Baixa, Pharmacy, Vila Joiosa, Spain
  7. 7Hospital Virgen de Los Lirios, Pharmacy, Alcoy, Spain
  8. 8Hospital General Universitario Dr. Balmis, Pharmacy, Alicante, Spain
  9. 9Hospital General Universitario de Elche, Statistical, Elche, Spain


Background and Importance Guselkumab is approved for the treatment of psoriasis and psoriatic arthritis. Nonetheless, patients who participate in clinical trials are quite different from those seen in daily clinical practice.

Aim and Objectives The objective of our study was to assess the effectiveness and drug survival in patients who suffer from psoriasis and psoriatic arthritis in real-life settings treated with guselkumab in eight hospitals in Valencian Community (Spain).

Material and Methods This was a multicentric retrospective study, adult patients with psoriasis and psoriatic arthritis and was approved by the Drug Research Ethics Committee (CEIm). We included patients who had previous exposure to one or more biologic drugs and received guselkumab (April 2019 to October 2022 (42 months)).

Results A total number of 184 patients with plaque psoriasis (81.5% n=150) or psoriatic arthritis (18.5% n=34) were enrolled in this study, with a predominance of male patients (52.2%; n = 88). Mean (± SD) age at the initiation of guselkumab therapy was 37,3 ± 17.0 for psoriasis patients and 47,1 ± 14,1 for psoriatic arthritis patients (p< 0.05).

About the previous lines of treatment they had been received: 91.8% (n=169) received one, 62.5% (n=115) received two and 44.0% (n=81) had received more than three previous lines. As first-line of treatment, 65.7% (n=111) had been treated with tumour necrosis factor (TNF) inhibitor, 17.2% (n=29) with IL-12/23 inhibitor, 8.3% (n=14) with IL17 inhibitors, 3.0% (n=5) with IL23 inhibitors, and 3.0% (n=5) with apremilast.

The mean (± SD) PASI score decreased from 7.6 ± 5.8 at baseline to 1.5 ± 6.8 after 24 weeks of therapy (p< 0.05), and to 0.0 ± 1.2 after 52 weeks (p<0.05). These results are similar to those observed in pivotal trials VOYAGE 1, VOYAGE 2 and NAVIGATE (1, 2, 3) Reason for discontinuation: loss of effectiveness 14 (7.6%), lost follow-up two (1.1%), security issues two (1.1%), and others six (3.3%). Overall cumulative drug survival was 87.0% at 42 months.

Conclusion and Relevance This multicentre retrospective study analysed data from eight hospitals, demonstrating effectiveness and drug survival of guselkumab in a real-world setting, similar to those observed in pivotal trials.

References and/or Acknowledgements 1. VOYAGE 1.

2. VOYAGE 2.


Conflict of Interest No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.